Abstract:Since α–secretase cleaves within the Aβ peptide domain, its activation may even have the double advantage of not only precluding the neurotoxic Aβ peptide formation but also generating the putatively neuroprotective sAPP–α. Thus, it would appear highly advantageous to shift APP cleavage from the amyloidogenic β–secretase to the non–amyloidogenic α–secretase cleavage. Indeed, we have recently shown that green tea polyphenol (–)–epigallocatechin–3–gallate (EGCG) exerts a beneficial role on reducing brain Aβ levels, resulting in mitigation of cerebral amyloidosis in a mouse model of Alzheimer's disease (AD). EGCG seems to accomplish this by modulating amyloid precursor protein (APP) processing, resulting in enhanced cleavage of the α–C–terminal fragment (α–CTF) of APP and corresponding elevation of the N–terminal APP product, soluble APP–α (sAPP–α). These beneficial effects were associated with increased α–secretase cleavage activity, but no significant alteration in β– or γ–secretase activities. To gain insight into the molecular mechanism whereby EGCG modulates APP processing, we evaluated the involvement of three candidate α–secretase enzymes, α–disintegrin–and–metalloprotease (ADAM) 9, 10, or 17, in EGCG–induced non–amyloidogenic APP metabolism. Results show that EGCG treatment of N2a cells stably transfected with “Swedish” mutant human APP (SweAPP N2a cells) leads to markedly elevated active (∼60 kDa mature form) ADAM10 protein. Elevation of active ADAM10 significantly correlated with increased α–CTF cleavage, and elevated sAPP–α in vitro and in vivo. To definitively test the contribution of ADAM10 to non–amyloidogenic APP metabolism, small interfering RNA knock–down of ADAM9, 10, or 17 mRNA was employed. Results show that ADAM10 (but not ADAM9 or 17) is critical for EGCG–mediated α–secretase cleavage activity. In summary, ADAM10 activation is necessary for EGCG promotion of non–amyloidogenic (α–secretase cleavage) APP processing. Thus, ADAM10 represents an important pharmacotherapeutic target for the treatment of cerebral amyloidosis in AD.

The Distinct Role of ADAM17 in APP Proteolysis and Microglial Activation Related to Alzheimer’s Disease

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

Amyloid precursor protein-processing products affect mononuclear phagocyte activation: pathways for sAPP- and Abeta-mediated neurotoxicity.

Amyloid precursor protein-processing products affect mononuclear phagocyte activation: pathways for sAPP- and Aβ-mediated neurotoxicity: Microglia-mediated oxidative neurotoxicity

Proteolytic processing of Alzheimer's β-amyloid precursor protein.

Therapeutic Approaches to Alzheimer'S Disease Through Stimulating of Non-Amyloidogenic Processing of Amyloid Precursor Protein

The Role of APP in Alzheimer’s Disease

sAPPα Peptide Promotes Damaged Microglia to Clear Alzheimer's Amyloid‐β via Restoring Mitochondrial Function

The Neuro-Inflammatory Microenvironment: an Important Regulator of Stem Cell Survival in Alzheimer’s Disease

The roles of amyloid precursor protein (APP) in neurogenesis: Implications to pathogenesis and therapy of Alzheimer disease.

Targeting Amyloidogenic Processing of APP in Alzheimer’s Disease

The Role of ADAM10 in Alzheimer’s Disease

Molecular and cellular mechanisms for Alzheimer's disease: understanding APP metabolism.

Advances in the β-amyloid precursor protein of Alzheimer's disease

Regulation of Alpha-Secretase ADAM10 In vitro and In vivo: Genetic, Epigenetic, and Protein-Based Mechanisms

ADAM10 and ADAM17 are degraded by lysosomal pathway via asparagine endopeptidase

P4–267: ADAM10 Activation is Required for Green Tea EGCG–induced Alpha–secretase Cleavage of Amyloid Precursor Protein

Amyloid Precursor Protein Revisited

The amyloid precursor protein: beyond amyloid

Modifications and Trafficking of APP in the Pathogenesis of Alzheimer's Disease

Microglial Aβ Receptors in Alzheimer’s Disease